December 24, 2014 | The Food & Drug Administration in the United States has approved Teva Pharmaceutical Company‘s GRANIX injection solution for sale and distribution in the US. GRANIX’s system works to hasten the flow of white blood cells and to strengthen the immune system, especially during chemotherapeutic treatments. GRANIX has been present on the American market since November 2013, but is currently only available for distribution at hospitals and by doctors. Now Teva plans to release a new version of the GRANIX injection device that can be self-dosed and injected by patients and medical service providers. Teva is Israel’s largest pharmaceutical company, founded in 1901 and managed by CEO and president Erez Vigodman.